脂加氧酶及其抑制剂研究进展  

Advances in studies on lipoxygenase and its inhibitors

作　　者：蒋丽萍[1] 陆阳[1] 陈红专[1] 

机构地区：[1]上海第二医科大学药物研究所,上海200025

出　　处：《中国药理学通报》2005年第8期897-901,共5页Chinese Pharmacological Bulletin

基　　金：国家自然科学基金(No30371731);上海第二医科大学基金资助项目(No2003HZJJ002)

摘　　要：脂加氧酶(lipoxygenase,LO)途径参与高血压、动脉粥样硬化和血管成型术后再狭窄等疾病的病理过程,并在诸疾病发展中起关键作用。LO抑制剂能明显降低血管收缩性,降低血压,抑制血管平滑肌细胞迁移,降低动脉损伤后新内膜增厚速率,减少活性氧(reactiveoxygenspecies,ROS)的生成,阻断细胞间结合反应。LO抑制剂的作用与阻断MAPK通路有关。阻断LO途径为防治心血管疾病提供了新的策略,因此LO可望成为防治心血管疾病药物的重要靶点。Lipoxygenase （LO） pathway had been implicated in the pathogenesis of such cardiovascular diseases as hypertension, atherosclerosis, restenosis, and palys and important role in the development of these disease. LO inhibitiors could suppress vascular contractile responses significantly, reduce blood pressure,inhibit migration of vascular smooth muscle cells （VSMC） , attenuate neointimal thickening in the injuried arteries and generation reactive oxygen species （ROS）, block monocyte binding to VSMC, etc. The effects of LO inhibitors were associated with marked inhibition of MAPK pathway. Therefore, inhibition of LO pathway may provide a new strategy for preventing and treating above diseases, suggesting that LO mat be a novel taget for such purposes.

关 键 词：脂加氧酶 脂加氧酶抑制剂 血管增生性疾病 靶点 

分 类 号：R-05[医药卫生] R329.24